Psilocybin shows promise in treating major depression, offering a more effective alternative to traditional pharmaceuticals. Unlike microdosing, macro doses facilitate enhanced brain connectivity, allowing for new perspectives on past experiences. Meanwhile, ibogaine, a longer and more complex psychedelic, is being explored in clinical trials, particularly in Kentucky, highlighting a growing acceptance of psychedelics in therapeutic settings.
